PCSK9 and atherosclerosis: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor considerably decreased LDL-C and could be useful in reducing the risk of events in patients with DM and ASCVD receiving maximally tolerated statin [32, 33].